Craig Chepke, MD, DFAPA

Idiopathic hypersomnia, characterized by excessive daytime sleepiness (EDS), has an estimated population prevalence up to 1.5%. Psychiatric medications may exacerbate EDS and, conversely, idiopathic hypersomnia treatments may exacerbate psychiatric...

Improved insomnia symptoms with lemborexant treatment may translate into improved daytime functioning.

Dysregulation of noradrenergic activity plays a key role in symptom presentation in major depressive disorder, schizophrenia, Alzheimer’s agitation, and PTSD. This article provides an expert panel’s consensus regarding the...

This study evaluated real-world treatment patterns for patients initiating benztropine and examined treatment approaches in patients with drug-induced movement disorders from a health care provider perspective.

As shown in this review, OSA may be a risk factor for the development of psychiatric conditions, as well as suicidal ideation and attempts.